Pasithea Therapeutics - Warrants (11/08/2026) Overview
Valuation check: KTTAW's P/E ratio is -0.23, below the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow-0.23
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, KTTAW shows a P/E ratio of -0.23. That is below the Healthcare sector average of 25.9. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.9. Pasithea Therapeutics - Warrants (11/08/2026) is at -0.23, which is lower that average. That is roughly 100.9% below the sector mean. Use the comparison chart on this page to see how KTTAW stacks up against individual peers as well.
Investors watch KTTAW's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Pasithea Therapeutics - Warrants (11/08/2026)'s latest reading is -0.23. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Pasithea Therapeutics - Warrants (11/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -0.23) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.9, while KTTAW is at -0.23. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
